Haemonetics (HAE)
(Delayed Data from NYSE)
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.15 USD
+0.21 (0.28%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $76.11 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Boston Scientific Gets a Boost From New Products, Buyouts
by Zacks Equity Research
Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.
Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls
by Zacks Equity Research
Exact Sciences (EXAS) revenue growth will likely beat expectations for both the fourth quarter and 2019.
NuVasive (NUVA) Stock Dips Despite Strong Preliminary Q4 Show
by Zacks Equity Research
NuVasive's (NUVA) revenue growth will likely beat expectations for both the fourth quarter and 2019.
Globus Medical Gains From International Spine Arm, Innovation
by Zacks Equity Research
Globus Medical (GMED) delivers solid spine sales globally. Enabling Technologies too rides high on the rising uptake of ExcelsiusGPS platform.
Integra Announces Preliminary Q4 Results, Share Buyback Plan
by Zacks Equity Research
Integra (IART) projects fourth-quarter 2019 revenues at or near the low end of its previously-announced guidance.
Boston Scientific Stock Dips on Dull Preliminary Q4 Results
by Zacks Equity Research
Boston Scientific's (BSX) organic revenue growth will likely lag expectations for both the fourth quarter and 2019.
Here's Why You Should Add Bruker (BRKR) to Your Portfolio Now
by Zacks Equity Research
Investor confidence in Bruker (BRKR) is at a high, thanks to solid prospects.
LabCorp Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
LabCorp (LH) is optimistic about maintaining its growth momentum on several recent developments.
CVS Health's Selling Seasons Strong, Omnicare Arm Upsets
by Zacks Equity Research
CVS Health's (CVS) 2020 PBM selling season remains strong with gross new business and net new business wins.
Hologic Posts Solid Preliminary Q1 Sales, Revises Buyback Plan
by Zacks Equity Research
Hologic (HOLX) expects to generate robust Surgical and Diagnostics revenues in Q1, though softness in the divested Medical Aesthetics business remains a concern.
Thermo Fisher Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Thermo Fisher (TMO) is optimistic about maintaining its growth momentum on several recent developments.
Medtronic's Neurostimulator DBS System Receives CE Mark
by Zacks Equity Research
Medtronic's (MDT) Percept PC neurostimulator DBS system, with BrainSense technology, receives the CE Mark, thus clearing the way for the treatment of various neurologic disorders in the EU.
Teleflex (TFX) Receives FDA Nod for Expanded Use of UroLift
by Zacks Equity Research
Teleflex (TFX) receives FDA clearance for expanded indication for the utilization of the UroLift System for treating larger prostrates in men.
Globus Medical Stock Up on Solid '19 Preliminary Results
by Zacks Equity Research
Per Globus Medical (GMED), it ends 2019 on a promising note with an apparently solid robotic pipeline and a speedy competitive recruiting.
Medtronic (MDT) Buys Stimgenics, To Present New Trial Results
by Zacks Equity Research
Medtronic (MDT) acquires Stimgenics to integrate DTM therapy in its pain therapies segment. It will also present trial results favoring the therapy at the upcoming NANS meeting.
Varian (VAR) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Varian (VAR) gains from several positive developments.
Abbott's Less-Invasive Surgery for Heart Pump Gets FDA Nod
by Zacks Equity Research
Abbott's (ABT) less invasive approach for heart surgery for its heart pump gets the FDA clearance, thus paving the way for avoiding open heart surgeries.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Teleflex (TFX) on its strong segmental and international performance in Q3.
Amedisys Gains on Favorable Demography, New Hospice Buyouts
by Zacks Equity Research
Amedisys (AMED) is steadily benefiting from its recent takeovers of hospice care providers, namely RoseRock Healthcare and Compassionate Care Hospice.
Exact Sciences Rides on Cologuard, Eyes Merger Synergies
by Zacks Equity Research
Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.
Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging
by Zacks Equity Research
The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.
Here's Why You Should Add STERIS (STE) to Portfolio Now
by Zacks Equity Research
Investor confidence is high on STERIS (STE) stock for now, thanks to its solid prospects.
Neogen Expands in South America With Productos Acquisition
by Zacks Equity Research
Neogen (NEOG) expands operations in South America by acquiring its food safety diagnostics distributor partner that operates in Argentina and Uruguay.
LabCorp (LH) Grows on Solid Diagnostics Arm Despite PAMA Headwinds
by Urmimala Biswas
LabCorp's (LH) Diagnostics business flourishes organically in terms of both revenues and volumes despite additional price reductions due to Protecting Access to Medicare Act (PAMA).
Here's Why You Should Hold on to Zimmer (ZBH) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Zimmer (ZBH) on its stellar segmental performance in Q3.